| __timestamp | Gilead Sciences, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3788000000 | 5903000 |
| Thursday, January 1, 2015 | 4006000000 | 2762000 |
| Friday, January 1, 2016 | 4261000000 | 1114000 |
| Sunday, January 1, 2017 | 4371000000 | 25573000 |
| Monday, January 1, 2018 | 4853000000 | 6000000 |
| Tuesday, January 1, 2019 | 4675000000 | 38845000 |
| Wednesday, January 1, 2020 | 4572000000 | 50523000 |
| Friday, January 1, 2021 | 6601000000 | 75463000 |
| Saturday, January 1, 2022 | 5657000000 | 105767000 |
| Sunday, January 1, 2023 | 6498000000 | 167512000 |
| Monday, January 1, 2024 | 28675800000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, Gilead Sciences, Inc. and Xenon Pharmaceuticals Inc. have shown contrasting trends in their cost of revenue. Gilead Sciences, a giant in the sector, saw its cost of revenue grow by approximately 72% over the decade, peaking in 2021. This reflects its expansive operations and market reach. In contrast, Xenon Pharmaceuticals, a smaller player, experienced a staggering increase of over 2,700% in the same period, highlighting its rapid growth and scaling efforts. By 2023, Xenon's cost of revenue reached about 2.6% of Gilead's, up from a mere 0.2% in 2014. These figures underscore the dynamic nature of the pharmaceutical landscape, where both established giants and emerging innovators play pivotal roles.
Cost of Revenue Comparison: AbbVie Inc. vs Gilead Sciences, Inc.
Analyzing Cost of Revenue: Novartis AG and Xenon Pharmaceuticals Inc.
Amgen Inc. vs Xenon Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Gilead Sciences, Inc. vs Insmed Incorporated: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Gilead Sciences, Inc. and Bio-Techne Corporation's Expenses
Cost of Revenue Trends: Gilead Sciences, Inc. vs Veracyte, Inc.
Cost Insights: Breaking Down Gilead Sciences, Inc. and Wave Life Sciences Ltd.'s Expenses
Cost of Revenue Trends: Gilead Sciences, Inc. vs Geron Corporation
Cost of Revenue Trends: Gilead Sciences, Inc. vs MiMedx Group, Inc.
Cost of Revenue: Key Insights for BeiGene, Ltd. and Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Pharming Group N.V. vs Xenon Pharmaceuticals Inc.